-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Survey: bluebird bio (NASDAQ:BLUE) and Vaxart (NASDAQ:VXRT)
Head-To-Head Survey: bluebird bio (NASDAQ:BLUE) and Vaxart (NASDAQ:VXRT)
bluebird bio (NASDAQ:BLUE – Get Rating) and Vaxart (NASDAQ:VXRT – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Risk and Volatility
bluebird bio has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
Get bluebird bio alerts:Insider and Institutional Ownership
96.4% of bluebird bio shares are owned by institutional investors. Comparatively, 45.9% of Vaxart shares are owned by institutional investors. 2.9% of bluebird bio shares are owned by company insiders. Comparatively, 2.8% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares bluebird bio and Vaxart's net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
bluebird bio | -2,141.34% | -130.19% | -73.31% |
Vaxart | -16,892.57% | -41.95% | -35.70% |
Analyst Recommendations
This is a breakdown of current recommendations for bluebird bio and Vaxart, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bluebird bio | 1 | 10 | 2 | 1 | 2.21 |
Vaxart | 0 | 1 | 2 | 0 | 2.67 |
bluebird bio currently has a consensus price target of $11.08, indicating a potential upside of 96.51%. Vaxart has a consensus price target of $13.00, indicating a potential upside of 199.54%. Given Vaxart's stronger consensus rating and higher probable upside, analysts clearly believe Vaxart is more favorable than bluebird bio.
Earnings & Valuation
This table compares bluebird bio and Vaxart's top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
bluebird bio | $3.66 million | 118.84 | -$819.38 million | ($8.32) | -0.68 |
Vaxart | $890,000.00 | 616.41 | -$70.47 million | ($0.64) | -6.78 |
Vaxart has lower revenue, but higher earnings than bluebird bio. Vaxart is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
About bluebird bio
(Get Rating)
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
About Vaxart
(Get Rating)
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
bluebird bio (NASDAQ:BLUE – Get Rating) and Vaxart (NASDAQ:VXRT – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
青鳥生物(納斯達克:Blue-Get Rating)和偉生(納斯達克:VXRT-Get Rating)都是小盤醫療公司,但哪一家是優勢業務?我們將根據兩家公司的估值、分析師建議、風險、股息、收益、機構持股和盈利能力的強弱對它們進行比較。
Risk and Volatility
風險和波動性
bluebird bio has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
藍鳥生物的貝塔係數為1.29,這表明其股價的波動性比標準普爾500指數高出29%。相比之下,Vaxart的貝塔係數為0.69,這表明其股價的波動性比標準普爾500指數低31%。
Insider and Institutional Ownership
內部人與機構持股
96.4% of bluebird bio shares are owned by institutional investors. Comparatively, 45.9% of Vaxart shares are owned by institutional investors. 2.9% of bluebird bio shares are owned by company insiders. Comparatively, 2.8% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
藍鳥生物96.4%的股份由機構投資者持有。相比之下,機構投資者持有Vaxart 45.9%的股份。藍鳥生物2.9%的股份由公司內部人士持有。相比之下,Vaxart 2.8%的股份由公司內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一家公司有望實現長期增長。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
bluebird bio | -2,141.34% | -130.19% | -73.31% |
Vaxart | -16,892.57% | -41.95% | -35.70% |
淨利潤率 | 股本回報率 | 資產回報率 | |
藍鳥傳記 | -2,141.34% | -130.19% | -73.31% |
Vaxart | -16,892.57% | -41.95% | -35.70% |
Analyst Recommendations
分析師建議
This is a breakdown of current recommendations for bluebird bio and Vaxart, as provided by MarketBeat.
這是由MarketBeat提供的藍鳥生物和Vaxart的當前推薦細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bluebird bio | 1 | 10 | 2 | 1 | 2.21 |
Vaxart | 0 | 1 | 2 | 0 | 2.67 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
藍鳥傳記 | 1 | 10 | 2 | 1 | 2.21 |
Vaxart | 0 | 1 | 2 | 0 | 2.67 |
bluebird bio currently has a consensus price target of $11.08, indicating a potential upside of 96.51%. Vaxart has a consensus price target of $13.00, indicating a potential upside of 199.54%. Given Vaxart's stronger consensus rating and higher probable upside, analysts clearly believe Vaxart is more favorable than bluebird bio.
藍鳥生物目前的共識目標價為11.08美元,表明潛在上行空間為96.51%。Vaxart的一致目標價為13美元,表明潛在上行空間為199.54%。考慮到Vaxart更高的共識評級和更高的可能上行空間,分析師們顯然認為Vaxart比藍鳥生物更有利。
Earnings & Valuation
收益與估值
This table compares bluebird bio and Vaxart's top-line revenue, earnings per share and valuation.
這張表格比較了藍鳥生物和Vaxart的營收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
bluebird bio | $3.66 million | 118.84 | -$819.38 million | ($8.32) | -0.68 |
Vaxart | $890,000.00 | 616.41 | -$70.47 million | ($0.64) | -6.78 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
藍鳥傳記 | 366萬美元 | 118.84 | -8.1938億美元 | ($8.32) | -0.68 |
Vaxart | $890,000.00 | 616.41 | -7047萬美元 | ($0.64) | -6.78 |
Vaxart has lower revenue, but higher earnings than bluebird bio. Vaxart is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
Vaxart的收入低於藍鳥生物,但收益高於藍鳥生物。Vaxart的市盈率低於藍鳥生物,這表明它目前是兩隻股票中更負擔得起的一隻。
About bluebird bio
關於藍鳥傳記
(Get Rating)
(獲取評級)
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
藍鳥生物公司是一家生物技術公司,研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel;用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel;以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。該公司的臨牀研究計劃包括評估Lovo-cel治療SCD患者的安全性和有效性的HGB-205、HGB-206和HGB-210;以及評估Beti-cel治療β-地中海貧血患者的安全性和有效性的HGB-204、HGB-205、HGB-207和HGB-212。它與Orchard治療有限公司、四十七公司和Magenta治療公司簽訂了戰略合作和許可協議。該公司前身為Genetix製藥公司,並於2010年9月更名為藍鳥生物公司。藍鳥生物公司成立於1992年,總部設在馬薩諸塞州劍橋市。
About Vaxart
關於Vaxart
(Get Rating)
(獲取評級)
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Vaxart,Inc.是一家臨牀階段的生物技術公司,致力於基於其專有口服疫苗平臺的口服重組蛋白疫苗的發現和開發。該公司的產品線包括諾沃克病毒疫苗,一種口服片劑疫苗,正處於Ib期臨牀試驗,與針對GI.1和GII 4型諾沃克病毒株的雙價口服片劑疫苗一起進行臨牀試驗;季節性流感疫苗,正處於治療H1流感感染的第二階段臨牀試驗;呼吸道合胞病毒疫苗;以及冠狀病毒疫苗,正處於治療SARS-CoV-2感染的第二階段臨牀試驗。它還在開發治療宮頸癌和人乳頭瘤病毒引起的異型增生的治療性疫苗。該公司總部設在加利福尼亞州舊金山南部。
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧